Dengue Vaccines Market, By End User (Hospitals, Government Institutes, NGOs), and By Region (Latin America, Middle East, Africa, and Rest of World) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Dengue Vaccines Market, By End User (Hospitals, Government Institutes, NGOs), and By Region (Latin America, Middle East, Africa, and Rest of World) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Dengue fever is a mosquito-borne viral infection causing a severe flu-like illness. Dengue vaccine is only recommended in those who have previously had dengue fever. It is given as three injections over a year. Dengue is most likely to affect individual’s tropical and subtropical countries. Increasing prevalence of dengue is expected to propel growth of the global dengue vaccine market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the global Dengue Vaccine and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global Dengue Vaccine based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Sanofi, Takeda Pharmaceutical Company Limited, GlaxoSmithKline, and Merck & Co.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global Dengue Vaccine report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Dengue Vaccine Market, By End User:
Hospitals
Government Institutes
NGOs
Dengue Vaccine Market, By Region:
Latin America
By End User
Hospitals
Government Institutes
NGOs
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Asia Pacific
By End User
Hospitals
Government Institutes
NGOs
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By End User
Hospitals
Government Institutes
NGOs
By Country:
GCC
Israel
Rest of Middle East
Africa
By End User
Hospitals
Government Institutes
NGOs
By Country:
South Africa
Central Africa
North Africa
Rest of World
By End User
Hospitals
Government Institutes
NGOs
Company Profiles
Sanofi *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Takeda Pharmaceutical Company Limited
GlaxoSmithKline
Merck & Co.
“*” marked represents similar segmentation in other categories in the respective section.